JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267135

Human PMAIP1 (Noxa) knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PMAIP1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human PMAIP1 (Noxa) knockout A549 cell line (AB267135)
  • Sanger seq

Unknown

Sanger Sequencing - Human PMAIP1 (Noxa) knockout A549 cell line (AB267135)

Allele-1 : 2 bp deletion in exon1

Cell Culture - Human PMAIP1 (Noxa) knockout A549 cell line (AB267135)
  • Cell Culture

Unknown

Cell Culture - Human PMAIP1 (Noxa) knockout A549 cell line (AB267135)

Representative images of PMAIP1 knockout A549 cells, low and high confluency examples (top left and right respectively) and wild-type A549 cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using an EVOS M5000 microscope.

Sanger Sequencing - Human PMAIP1 (Noxa) knockout A549 cell line (AB267135)
  • Sanger seq

Unknown

Sanger Sequencing - Human PMAIP1 (Noxa) knockout A549 cell line (AB267135)

Allele-2 : 1 bp insertion in exon 1.

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267135-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267135-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267135 Human PMAIP1 (Noxa) knockout A549 cell line", "number":"AB267135-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267135-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267135-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267135 Human PMAIP1 (Noxa) knockout A549 cell line", "number":"AB267135-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267135-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267135 Human PMAIP1 (Noxa) knockout A549 cell line", "number":"AB267135-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267135-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267135 Human PMAIP1 (Noxa) knockout A549 cell line", "number":"AB267135-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PMAIP1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Noxa also known as PMAIP1 is a pro-apoptotic member of the Bcl-2 protein family. It has a molecular weight of approximately 20 kDa. Noxa commonly expresses in a number of tissues including lymphoid and myeloid lineages. It functions by interacting with other Bcl-2 family proteins like Mcl-1 promoting apoptosis through binding and neutralization of anti-apoptotic proteins. This interaction facilitates the release of cytochrome c from the mitochondria triggering caspase activation and subsequent apoptosis.
Biological function summary

Noxa plays a role in the regulation of programmed cell death including being part of multiprotein complexes within the mitochondria. Noxa's expression is upregulated in response to various cellular stress signals. These stresses include DNA damage and hypoxia where it acts to mediate apoptosis preventing the survival of cells with potential mutations. Its role in modulating apoptosis makes it key in maintaining cellular homeostasis.

Pathways

Noxa is involved in significant apoptotic and cellular stress response pathways. It forms part of the intrinsic apoptosis pathway which is tightly regulated by Bcl-2 family members like BAK and BAX. Noxa's ability to neutralize Mcl-1 allows the activation of these proteins committing the cell to apoptosis. It also participates in the p53 signaling pathway which is important for the cellular response to DNA damage wherein p53 directly transactivates Noxa.

Noxa is important in cancer and autoimmune syndromes. In cancer its expression often correlates with the sensitivity of cancer cells to chemotherapy as its role in apoptosis can enhance the elimination of cancerous cells. Mutations in p53 that impair its function can lead to decreased Noxa expression and apoptosis contributing to cancer progression. In autoimmune disorders aberrant regulation of apoptosis sometimes involving Noxa and its interaction with Bcl-2 proteins can result in premature cell death or survival of autoreactive cells exacerbating the disease.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com